<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28671597</article-id><article-id pub-id-type="pmc">5620603</article-id><article-id pub-id-type="doi">10.3390/ph10030059</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-10-00059</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Precipitation and Neutralization of Heparin from Different Sources by Protamine Sulfate</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hogwood</surname><given-names>John</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-10-00059">1</xref><xref rid="c1-pharmaceuticals-10-00059" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Mulloy</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="af2-pharmaceuticals-10-00059">2</xref></contrib><contrib contrib-type="author"><name><surname>Gray</surname><given-names>Elaine</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-10-00059">1</xref><xref ref-type="aff" rid="af2-pharmaceuticals-10-00059">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Vanden Eynde</surname><given-names>Jean Jacques</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-10-00059"><label>1</label>National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Herts EN6 3QG, UK; <email>elaine.gray@nibsc.org</email></aff><aff id="af2-pharmaceuticals-10-00059"><label>2</label>Institute for Pharmaceutical Sciences, King&#x02019;s College London, 10 Stamford Street, London SE1 9HN, UK; <email>barbara.mulloy@kcl.ac.uk</email></aff><author-notes><corresp id="c1-pharmaceuticals-10-00059"><label>*</label>Correspondence: <email>john.hogwood@nibsc.org</email>; Tel.: +44-1707-641-480</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2017</year></pub-date><volume>10</volume><issue>3</issue><elocation-id>59</elocation-id><history><date date-type="received"><day>08</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Current therapeutic unfractionated heparin available in Europe and US is of porcine mucosal origin. There is now interest, specifically in the US, to use bovine mucosa as an additional source for the production of heparin. The anticoagulant action of heparin can be neutralized by protamine sulfate, and in this study the ability of protamine to bind and neutralize the anticoagulant activities of heparin from porcine mucosa, bovine mucosa and bovine lung were assessed. Protamine sulfate was able to bind and precipitate similar amounts of heparins from different sources on a mass basis. However, differential amounts of anticoagulant activities were neutralized by protamine sulfate, with neutralization of porcine mucosa more effective than for bovine lung and bovine mucosa. For all heparins, potentiation of thrombin inhibition by antithrombin and heparin cofactor II was preferentially neutralized over antithrombin-mediated inhibition of factor Xa or plasma clotting time. Whole blood thromboelastography showed that neutralization by protamine sulfate was more effective than the antithrombin dependent thrombin inhibition assays indicated. While there was no absolute correlation between average or peak molecular weight of heparin samples and neutralization of anticoagulant activity, correlation was observed between proportions of material with high affinity to antithrombin, specific activities and neutralization of activity.</p></abstract><kwd-group><kwd>heparin</kwd><kwd>protamine sulfate</kwd><kwd>neutralization</kwd></kwd-group></article-meta></front><body><sec id="sec1-pharmaceuticals-10-00059"><title>1. Introduction</title><p>Contamination of porcine heparin with oversulfated chondroitin sulfate in 2007/2008 [<xref rid="B1-pharmaceuticals-10-00059" ref-type="bibr">1</xref>] led to rapid revisions to pharmacopoeial monographs. The principal changes made to the United States Pharmacopeia (USP) and European Pharmacopeia (EP) monographs for heparin included specifying the source as porcine intestinal mucosa, adoption of a purified reagent assay based on antithrombin inhibition of thrombin for potency determination and a specific activity of not less than 180 IU/mg [<xref rid="B2-pharmaceuticals-10-00059" ref-type="bibr">2</xref>]. Furthermore, the contamination issue highlighted the primary reliance on a single source for clinical heparin, porcine mucosa, in Europe and the US. There is now interest in diversifying the supply of heparin, with bovine mucosa suggested as an alternative source [<xref rid="B3-pharmaceuticals-10-00059" ref-type="bibr">3</xref>].</p><p>Heparin is a complex heterogeneous and polydisperse anionic polysaccharide, consisting of alternating glucosamine and uronic acid monosaccharide residues [<xref rid="B4-pharmaceuticals-10-00059" ref-type="bibr">4</xref>]. Its primary use is as an anticoagulant and antithrombotic agent for surgery and extracorporeal circuits [<xref rid="B5-pharmaceuticals-10-00059" ref-type="bibr">5</xref>]. Heparin is the anticoagulant of choice for these indications as it can be readily reversed by protamine sulfate [<xref rid="B6-pharmaceuticals-10-00059" ref-type="bibr">6</xref>], an arginine rich basic protein [<xref rid="B7-pharmaceuticals-10-00059" ref-type="bibr">7</xref>]. The use of protamine sulfate is not without some risk [<xref rid="B8-pharmaceuticals-10-00059" ref-type="bibr">8</xref>], and there has been interest in alternative compounds which can neutralize heparin activity [<xref rid="B9-pharmaceuticals-10-00059" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-10-00059" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceuticals-10-00059" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-10-00059" ref-type="bibr">12</xref>]. However, such investigations have been limited in scope, primarily involving in vitro experimentation. In an animal model [<xref rid="B10-pharmaceuticals-10-00059" ref-type="bibr">10</xref>], a synthetic compound with lower immunogenicity was found to be able to neutralize heparin comparably to protamine. Despite the interest in alternatives to protamine sulfate, until clinical evaluations are carried out it will remain the heparin neutralization agent of choice.</p><p>Porcine intestinal mucosa (PM) heparins have been used extensively for over 50 years, with gradual improvements in quality and specific activity [<xref rid="B13-pharmaceuticals-10-00059" ref-type="bibr">13</xref>]. Bovine heparins, whilst clinically used in South America, have not been subjected to extensive study until recently [<xref rid="B14-pharmaceuticals-10-00059" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceuticals-10-00059" ref-type="bibr">15</xref>]. Primary observations are that bovine and porcine heparins have structural differences [<xref rid="B14-pharmaceuticals-10-00059" ref-type="bibr">14</xref>] such as lower weight average molecular weight for bovine lung (BL) heparin, and a lower proportion of 6-<italic>O</italic>-sulfo groups in bovine intestinal mucosa (BM) heparin. Bovine heparins also have lower specific activities [<xref rid="B16-pharmaceuticals-10-00059" ref-type="bibr">16</xref>], with values consistently below the new minimum monograph potency requirement. The lower specific activity would mean that greater amounts by mass of bovine heparin would be required to achieve the same dose in units of activity.</p><p>There is limited information on the ability of protamine sulfate to neutralize the activity of heparin from different sources. Recent interest in the interaction between protamine sulfate and heparin has centered on the possible immunogenic nature of large macromolecular protamine&#x02013;heparin complexes [<xref rid="B17-pharmaceuticals-10-00059" ref-type="bibr">17</xref>]. Some previous work has shown that high molecular weight heparins have a higher affinity for protamine [<xref rid="B18-pharmaceuticals-10-00059" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceuticals-10-00059" ref-type="bibr">19</xref>], with these studies carried out with porcine unfractionated or low molecular weight heparins. Independent of molecular weight, protamine sulfate has also been shown to neutralize more effectively antithrombin dependent inhibition of thrombin than the antithrombin inhibition of factor Xa [<xref rid="B19-pharmaceuticals-10-00059" ref-type="bibr">19</xref>]. The clinical dosage of protamine sulfate as recommended by the manufacturers is related to the pharmacopoeial methods for bioidentity of protamine sulfate which specify that 1 mg of protamine should precipitate not less than 100 international units (IU) of heparin reference standards. However, it is not clear how the precipitation of heparin relates to neutralization of anticoagulant activity of heparin.</p><p>The main objective of this study was to investigate the relationship between precipitation and neutralization of porcine and bovine heparins with protamine sulfate. Accurate anticoagulant activities were determined for a range of PM, BM and BL heparins and used to ascertain whether the units of heparin as measured by heparin/protamine sulfate precipitation related to neutralization of activity. The results from the current study indicate that there are differences in the precipitation and neutralization of biological activity of the heparins by protamine sulfate, and that neutralization of anticoagulant activities by the same amount of protamine sulfate is different for heparin from different sources.</p></sec><sec id="sec2-pharmaceuticals-10-00059"><title>2. Results</title><sec id="sec2dot1-pharmaceuticals-10-00059"><title>2.1. Anticoagulant Activity of Heparin Samples</title><p>The anticoagulant activities were estimated against the 6th International Standard for Unfractionated Heparin (07/328, NIBSC, South Mimms, UK), a PM heparin. All activity assays: antithrombin-dependent anti-Xa (AT:aXa), antithrombin-dependent anti-IIa (AT:aIIa), human plasma anticoagulant activated thromboplastin time (APTT) and heparin cofactor II dependent anti-IIa (HCII:aIIa) were valid by parallelism and linearity criteria using the statistical package, Combistats 5.0 (EDQM, Strasbourg, France). The activities of fifty-two PM heparins (<xref ref-type="fig" rid="pharmaceuticals-10-00059-f001">Figure 1</xref>) were similar (AT:aXa 190, AT:aIIa 186, APTT 185, HCII:aIIa 193 IU/mg) irrespective of the method used (ANOVA, <italic>p</italic> = 0.23). For twenty-six batches of BM heparin samples, there was significant difference between the different assay methods (ANOVA <italic>p</italic> &#x0003c; 0.0001). However, there was no significant difference between results for AT:aXa (127 IU/mg) and APTT (133 IU/mg) activities when considered independently of the other assay methods (<italic>p</italic> &#x0003e; 0.01). AT:aIIa potencies (107 IU/mg) were lower and the HCII:aIIa activities (165 IU/mg) were higher than AT:aXa and APTT estimates. For ten batches of bovine lung heparin, the AT:aXa, AT:aIIa and APTT (130, 127, 121 IU/mg respectively) activities were similar (ANOVA, <italic>p</italic> &#x0003e; 0.01), but HCII:aIIa (220 IU/mg) activity was significantly higher than all other activities (ANOVA, <italic>p</italic> &#x0003c; 0.0001).</p><p>With the exception of HCII:aIIa for bovine lung heparin, PM heparin had higher anticoagulant activities (<xref ref-type="fig" rid="pharmaceuticals-10-00059-f001">Figure 1</xref>) than BM and BL heparins. BM and BL heparins had similar activities by AT:aXa (127 to 131 IU/mg), but different activities by AT:aIIa (107 to 127 IU/mg) and by APTT (133 to 121 IU/mg). The higher average HCII:aIIa activity of BL heparin (220 IU/mg) compared to PM heparin (193 IU/mg) and BM heparin (165 IU/mg) was influenced by three out of 10 BL heparin samples having exceptionally high activities, thus raising the overall average HCII:aIIa value. When the median HCII:aIIa activity is compared, BL heparin (203 IU/mg) is only slightly higher than PM heparin (191 IU/mg).</p></sec><sec id="sec2dot2-pharmaceuticals-10-00059"><title>2.2. Protamine Sulfate Precipitation Assay</title><p>The European Pharmacopeia (EP) monograph states that 1 mg of protamine sulfate precipitates not less than 100 IU of Biological Reference Preparation (BRP) heparin standard. A selection of 16 PM, 16 BM and 4 BL heparin samples were used in the precipitation assay (<xref ref-type="fig" rid="pharmaceuticals-10-00059-f002">Figure 2</xref>). For this set of experiments, the quantity of heparin (based on AT:aIIa unitage) needed to precipitate 1 mg protamine sulfate was measured. Broadly, greater amounts of PM heparins by activity (average of 126 AT:aIIa IU, ranging 103&#x02013;142 AT:aIIa IU) were required to precipitate protamine sulfate than BM heparin (an average of 79 IU AT:aIIa, ranging from 48&#x02013;96 AT:aIIa IU) and BL heparins (an average of 84, ranging from 79&#x02013;95 AT:aIIa IU).</p><p>Based on the AT:aIIa specific activity estimated, the corresponding amounts of heparin in terms of mass were recalculated from the amount in IU. The heparin by mass which precipitated 1 mg of protamine sulfate is shown in <xref ref-type="fig" rid="pharmaceuticals-10-00059-f003">Figure 3</xref>. By contrast, the average mass concentration required to precipitate the same amount of protamine sulfate was the same for all the heparins, PM 0.76 mg, BM 0.76 mg and BM 0.74 mg. <xref ref-type="table" rid="pharmaceuticals-10-00059-t001">Table 1</xref> shows that on an IU basis PM and BM are clearly different (<italic>p</italic> &#x0003c; 0.001), but on an mg basis the same amount of heparin was needed to precipitate 1 mg of protamine sulfate.</p></sec><sec id="sec2dot3-pharmaceuticals-10-00059"><title>2.3. Neutralization of Heparin Activity</title><p>Four samples each of PM, BM and BL heparin, spanning the range of specific activities by AT:aIIa assays, were investigated further (<xref ref-type="table" rid="pharmaceuticals-10-00059-t002">Table 2</xref>) for neutralization of activities. With a fixed amount of heparin mixed with a fixed concentration of protamine sulfate, the remaining amount of heparin by precipitation and by anticoagulant activity was estimated (<xref ref-type="fig" rid="pharmaceuticals-10-00059-f004">Figure 4</xref>).</p><p>In general, for all the samples, protamine sulfate was able to neutralize more biological activity than the precipitation assays indicated. For PM heparin, the anticoagulant activity through HCII was more readily neutralized than antithrombin dependent activity or plasma based activity (<xref ref-type="fig" rid="pharmaceuticals-10-00059-f004">Figure 4</xref>). For example, for sample P1, the remaining activities by AT:aIIa, AT:aXa, APTT and HCII:aIIa were 17.5, 25.6, 28.5 and 3.5 IU respectively. The ranking order for neutralization was HCII:aIIa &#x0003e; AT:aIIa &#x0003e; AT:aXa = APTT across the four samples. For BM heparin, HCII and AT:aIIa were neutralized to a similar extent, and AT:aXa and APTT neutralization were also similar to each other. For example, for sample B1 the remaining activities by AT:aIIa, AT:aXa, APTT and HCII:aIIa were 43.4, 69.7, 74.1 and 37.7 IU respectively. The ranking order for neutralization was HCII:aIIa = AT:aIIa &#x0003e; AT:aXa = APTT. The BL heparin ranking order for neutralization was HCII:aIIa &#x0003e; AT: aIIa &#x0003e; APTT &#x0003e; AT:aXa. When comparing the differences between neutralization and precipitation, only the BM samples had values which were similar. This is illustrated by the remaining level of anticoagulant activity in BM samples by AT:aXa (69.7, 56.5, 59.8, 71.4 IU) and APTT (74.1, 57.9, 65.2, 72.0 IU) were similar to the precipitation values (59.5, 54.5, 65.5, 70.5 IU).</p><p>The average amount of heparin which protamine sulfate can precipitate or neutralize is shown in <xref ref-type="table" rid="pharmaceuticals-10-00059-t003">Table 3</xref>. Protamine sulfate neutralized more activity in BM, 123 AT:aIIa IU/mg, than indicated by precipitation, 75 IU/mg, a 64% difference. The difference between neutralization and precipitation for BL heparin was 56%, 131 and 84 IU/mg respectively. Neutralization of PM heparin by protamine sulfate was also higher than precipitation indicated, 161 IU/mg from 131 IU/mg. For all heparins, neutralization of anticoagulant activity measured by AT:aIIa was higher than indicated by precipitation. Calculation using the specific activities of the heparins for a mass/mass interaction between the heparins and protamine sulfate showed that by neutralization the amount of heparin required was no longer similar as shown by the precipitation assay.</p></sec><sec id="sec2dot4-pharmaceuticals-10-00059"><title>2.4. Thromboelastography</title><p>The thromboelastography activated clotting time (ACT) and whole blood APTT clotting time is shown in <xref ref-type="fig" rid="pharmaceuticals-10-00059-f005">Figure 5</xref>. For both ACT and APTT, the clotting times were different for each donor (<italic>n</italic> = 6) with and without heparin (data not shown). The reported clotting times for each heparin sample are the averaged clotting times from all donors and have each been blank corrected (heparin clotting times minus heparin-free clotting time).</p><p>The same amount by AT:aIIa activity of each heparin was used to prepare the samples using each donor&#x02019;s blood. The ACT measured was significantly different between the samples, PM to BM <italic>p</italic> = 0.002, PM to BL <italic>p</italic> = 0.046, and BM to BL <italic>p</italic> = 0.001. In the APTT assays, there was a difference between the PM and BM (<italic>p</italic> = 0.004), the BM and BL (<italic>p</italic> = 0.001) but not between PM and BL (<italic>p</italic> = 0.157).</p><p>The addition of protamine sulfate reduced the anticoagulant activity in all heparin samples. The reduction in clotting times was more pronounced for PM than BM or BL (average ACTs decreased from 341 to 62s, 462 to 207s and 306 to 116s respectively). The order of neutralization was PM, BL and BM, the same as that seen in the anticoagulant assays (<xref ref-type="fig" rid="pharmaceuticals-10-00059-f004">Figure 4</xref>).</p></sec><sec id="sec2dot5-pharmaceuticals-10-00059"><title>2.5. Molecular Weight</title><p>Molecular weights for the heparin samples are shown in <xref ref-type="table" rid="pharmaceuticals-10-00059-t004">Table 4</xref>. Except for one BM sample, B2, porcine heparins had higher molecular weights than the bovine heparin samples. The peak molecular weight, number average and weight average molecular weights for the bovine lung samples were lower than BM heparin. The polydispersity for all the heparins was comparable for each heparin type, ranging from 1.20 to 1.29.</p></sec><sec id="sec2dot6-pharmaceuticals-10-00059"><title>2.6. Antithrombin Titration Assay</title><p>The amount of antithrombin high affinity binding material in each heparin sample is shown in <xref ref-type="fig" rid="pharmaceuticals-10-00059-f006">Figure 6</xref>. The PM samples had a similar quantity of high affinity material to each other, with the average level 52%. The BM heparins had an average 30% high affinity material with little difference between the samples. The level of high affinity material in BL heparin was more variable, ranging from 25 to 40% and an average of 33%. The amount of antithrombin binding high affinity material was higher in PM heparin than both BM and BL (about 70% and 60% more respectively).</p></sec></sec><sec id="sec3-pharmaceuticals-10-00059"><title>3. Discussion</title><p>In this study, we show that the specific activities of PM, BM and BL heparins are different. The potency labelling assay, antithrombin dependent inhibition of thrombin (AT:aIIa), gave much lower values for both BM heparin and BL heparin samples when compared to PM heparin which confirms previous observations [<xref rid="B14-pharmaceuticals-10-00059" ref-type="bibr">14</xref>,<xref rid="B20-pharmaceuticals-10-00059" ref-type="bibr">20</xref>]. Of note, all the samples tested gave statistically valid results for all the activity assays against the 6th International Standard for Unfractionated Heparin. This indicates that the International Standard, a PM heparin, is a suitable potency standard not only for PM heparin but also for BM and BL heparins.</p><p>The pharmacopoeial specifications for PM heparin are for potency, a specific activity not less than 180 IU/mg or USP U/mg, and for identity a ratio of AT:aIIa/AT:aXa values within 0.9 to 1.1. All PM heparins passed the identity criterion and most passed the specific activity requirement of &#x0003e;180 IU/mg. PM heparins also gave anticoagulant activities by APTT and HCII:aIIa assays that were similar to the antithrombin dependent assays. Both BM and BL heparins have lower specific activity than the &#x0003e;180 IU/mg required for PM heparin. Furthermore, BM heparin had an AT:aIIa/AT:aXa ratio that was outside the 0.9&#x02013;1.1 criteria, with a calculated average of 1.2. It has been suggested that it will be unlikely for manufacturers to achieve the 180 IU/mg criteria for bovine heparin samples [<xref rid="B20-pharmaceuticals-10-00059" ref-type="bibr">20</xref>] and the data here support this. It should be noted that the lower specific activities of the bovine heparins indicate that more heparin in terms of mass would be required to achieve a similar anticoagulant effect to PM heparin.</p><p>The reversal of PM heparin post-operatively by protamine sulfate has been well established [<xref rid="B21-pharmaceuticals-10-00059" ref-type="bibr">21</xref>]. Protamine sulfate quality is assessed by a straightforward titration assay with heparin, with the minimal requirement that 1 mg precipitates not less than 100 IU of the pharmacopoeial reference preparations which are porcine heparins. However, it is unclear whether 1 mg protamine sulfate will precipitate as much as 100 IU of BM or BL heparin. The current study has shown that 1 mg protamine sulfate precipitated less than 100 IU of bovine heparins.</p><p>Irrespective of the specific activities of the samples, the amount of heparin in mass needed to precipitate a given quantity of protamine sulfate is the same for all heparins. In terms of activity units however, the ability of heparin to precipitate protamine sulfate was linked to the specific activities of the various heparins. A lower specific activity results in an increased concentration in units of heparin being required to precipitate a given amount of protamine sulfate.</p><p>The precipitation assay for protamine sulfate assesses the quality of protamine sulfate (a bio-identity test) and does not provide an indication of its ability to neutralize heparin activity. The use of a fixed activity of heparin for all preparations along with a fixed amount of protamine sulfate allowed for the estimation of the amount of activity neutralized. For all samples, the ability of protamine sulfate to neutralize activity was higher than would be predicted from the amount of heparin that can be precipitated. As expected, the use of fixed activity with a fixed amount of protamine showed that PM heparins, with have higher specific activities, were more effectively neutralized than BM and BL heparins.</p><p>Broadly, the thrombin based assays were more readily neutralized which may be due to the extended heparin chain length being more critical for these methods [<xref rid="B22-pharmaceuticals-10-00059" ref-type="bibr">22</xref>]. However, despite PM heparins having higher molecular weight than the BM and BL heparins, there is no significant correlation between the neutralization of activity and the molecular weight profiles of the heparin tested. The anti-Xa and plasma APTT anticoagulant activities were neutralized to a similar degree. The interaction between negatively charged heparin and positively charged protamine sulfate will favour the longer oligosaccharides in heparin [<xref rid="B19-pharmaceuticals-10-00059" ref-type="bibr">19</xref>] and as shown here influence antithrombin dependent thrombin inhibition activity which requires a minimum heparin molecular weight of about 5400 [<xref rid="B16-pharmaceuticals-10-00059" ref-type="bibr">16</xref>].</p><p>Clinically protamine sulfate will be administered by perfusion in order to neutralize heparin, and neutralization can be assessed using thromboelastography. This point-of-care technique is used with patient whole blood, where success of heparin neutralization is assessed by observing the time at which responses return to baseline. In this study, a controlled approach with the same amount of heparin, 1 IU anti-IIa, spiked into whole blood was used. We showed that the clotting times for each heparin type were different. In addition, at the same potency (AT:aIIa units), BM heparin gave longer activated clotting times than both PM and BL. The addition of protamine sulfate gave a reduction in clotting times for all samples, with the greatest reduction in PM, then BL and finally BM. This matched the profile of responses for the anticoagulant assays.</p><p>Fluorescence titration with antithrombin showed that PM heparin has a higher proportion of high affinity binding material than both BL and BM heparins. This correlates with the higher specific activity seen for PM heparin, and also explains the greater effectiveness of protamine sulfate at neutralizing the activity of PM heparin. Whilst having similar proportions of high affinity binding material and antithrombin dependent inhibition, BM and BL heparins show some differences in neutralization profiles. Neutralization of BL heparin is slightly greater than for BM heparin, which coincides with the slightly higher anti-IIa specific activity for bovine lung heparin.</p><p>For therapeutic purposes, an increase in mass of BM or BL heparin would be required to achieve the same therapeutic dose in International or USP Units of PM heparin. Based on the results of this study, it would be important to assess whether the current regimen of neutralization by protamine sulfate would need to be revised.</p></sec><sec id="sec4-pharmaceuticals-10-00059"><title>4. Materials and Methods</title><sec id="sec4dot1-pharmaceuticals-10-00059"><title>4.1. Materials</title><p>PM, BM and BL heparin samples were from the NIBSC archive of heparin samples, donated by several manufacturers. All heparin samples were subjected to a freeze dry step for 24 h prior to testing. Protamine sulfate was from Wockhardt UK Ltd, Wrexham, UK.</p></sec><sec id="sec4dot2-pharmaceuticals-10-00059"><title>4.2. Anticoagulant Assays</title><p>Anticoagulant activity was estimated against the 6th International Standard for Unfractionated Heparin (07/328, NIBSC, South Mimms, UK). Antithrombin dependent anti-Xa (AT:aXa) and anti-IIa (AT:aIIa) activities were carried out in accordance to the USP Monograph (USP 34 NF 29). Briefly, heparin samples are mixed with purified antithrombin (NIBSC, South Mimms, UK) prior to the addition of thrombin (FIIa) (NIBSC, South Mimms, UK) or factor Xa (Diagnostic Reagents, Thame, UK). After incubation a specific chromogenic substrate (S2238 and S2765 respectively, Werfen Ltd, Warrington, UK) was added, and the colour developed is inversely proportional to the amount of heparin. APTT assay was carried out in accordance with the European Monograph (01/2008:20705) but with human pooled plasma used instead of sheep plasma. Briefly, heparin samples are mixed with plasma to which an APTT regent (APTT-SP, Werfen Ltd, Warrington, UK) is added. After incubation, calcium chloride was added and the clotting time measured, which is directly proportional to the amount of heparin present. Heparin cofactor II dependent activity (HCII:aIIa) was measured by substitution of antithrombin with heparin cofactor II (Enzyme Research, Swansea, UK) in the USP anti-IIa method, and prolongation of the incubation steps from one to seven minutes [<xref rid="B23-pharmaceuticals-10-00059" ref-type="bibr">23</xref>].</p><p>All activities were estimated and assessed for statistical validity using the parallel line model in the statistics package Combistats 5.0 (EDQM, Strasbourg, France).</p></sec><sec id="sec4dot3-pharmaceuticals-10-00059"><title>4.3. Protamine Sulfate Precipitation Assay</title><p>The titration method, as described in the European Monograph for protamine sulfate (01/2017:0569), was adapted for use with the heparin samples. This method as described is a titration assay for protamine sulfate, where the requirement is that 1 mg of protamine sulfate precipitates not less than 100 IU of heparin sodium BRP. The method was adapted to allow for the calculation of heparin IU which precipitates 1 mg of protamine sulfate. Briefly, increasing volumes of heparin were added to a fixed concentration of protamine sulfate until a sharp increase in optical density was observed (wavelength is not critical). The sharp increase was then used to calculate the amount of heparin which has precipitated protamine sulfate.</p></sec><sec id="sec4dot4-pharmaceuticals-10-00059"><title>4.4. Heparin/Protamine Sulfate Complex</title><p>Several heparin samples, 4 each of PM, BM and BL, were diluted to 200 anti-IIa IU/mL and either mixed with an equal volume of 1 mg/mL protamine sulfate or deionised water. Anticoagulant activity, as above, was then measured for all prepared samples.</p></sec><sec id="sec4dot5-pharmaceuticals-10-00059"><title>4.5. Whole Blood Assays</title><p>Citrated whole blood was obtained through the National Blood and Transfusion Service (NBTS, New Brunswick, NJ, USA) and used to dilute samples of heparin (100 IU/mL) and heparin/protamine sulfate (100 IU/mL, 0.5 mg/mL) as described in <xref ref-type="sec" rid="sec4dot4-pharmaceuticals-10-00059">Section 4.4</xref>. The clotting time of each sample, diluted 100 fold in whole blood, was measured by Activated Partial Thromboplastin Time (APTT) in a KC4 coagulometer. The activated clotting time was measured using thromboelastography (TEG, Haemonetics, Coventry, UK) with tissue factor (14/302, NIBSC, South Mimms, UK) and calcium chloride as the activating reagent.</p></sec><sec id="sec4dot6-pharmaceuticals-10-00059"><title>4.6. Molecular Weights</title><p>Molecular weights for all samples were determined using size-exclusion chromatography with the USP Heparin Sodium Molecular Weight Calibrant RS (US Pharmacopeial Convention, MD, USA) as the broad standard calibrant as previously described [<xref rid="B24-pharmaceuticals-10-00059" ref-type="bibr">24</xref>].</p></sec><sec id="sec4dot7-pharmaceuticals-10-00059"><title>4.7. Antithrombin Fluorescent Titration</title><p>The binding of heparin to antithrombin was assessed using a fluorescence titration assay [<xref rid="B25-pharmaceuticals-10-00059" ref-type="bibr">25</xref>]. This method, which relies on a change in intrinsic fluorescence of antithrombin when bound to heparin, was adapted for use in a microtitre plate. All materials were diluted in 50 mM TRIS, 150 mM NaCl, 10 mM EDTA, 0.05% Tween-20 pH 7.4 buffer (all reagents from, Sigma, UK). A fixed concentration of antithrombin (NIBSC, South Mimms, UK) was placed into each well in a microplate, and increasing concentrations of heparin, 0 to 100 &#x000b5;g/mL, or fondaparinux (USP Fondaparinux Sodium for Assay, USP, Rockville, MD, USA), 0 to 6 &#x000b5;g/mL were added across wells. The increase in fluorescence (&#x003bb;<sub>EX</sub> 280 nm, &#x003bb;<sub>EM</sub> 340 nm) was measured and using the equation: &#x00394;F<sub>[H]</sub> = (F<sub>[H]</sub>&#x02013;F0)/(Fm&#x02013;F0), where F<sub>[H]</sub> is measured fluorescence at a concentration of heparin [H], F0 is basal fluorescence and Fm is maximum fluorescence, a chart was plotted of &#x00394;F<sub>[H]</sub> vs heparin concentration. From this chart, the amount of high affinity material in heparin which binds to antithrombin was calculated as the heparin concentration value at &#x00394;F<sub>[H]</sub> = Fm on an extrapolated straight line fitted to the first five heparin concentration points. The percentage high affinity material was then calculated using the concentration of antithrombin, where the molar concentration was estimated based on the assumption of 1:1 binding between antithrombin and fondaparinux, and molar concentration of heparin, calculated using number average molecular weight.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>Heparin manufacturers who donated heparin samples to the NIBSC heparin panel: Aspen Oss BV; BioIberica SA; Kin Master Produtos Quimicos Ltda; Opocrin SpA; Pfizer; Sanofi Aventis; Welding GmbH &#x00026; Co; Wockhardt Ltd. Peter Rigsby, Head of BioStatistics at NIBSC for helpful advice on analysis of data.</p></ack><notes><title>Author Contributions</title><p>John Hogwood and Elaine Gray conceived and designed the experiments; John Hogwood performed the experiments and analyzed the data; Barbara Mulloy provided guidance on antithrombin titration assays and analysis of data; John Hogwood, Elaine Gray and Barbara Mulloy wrote the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-10-00059"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishimoto</surname><given-names>T.K.</given-names></name><name><surname>Viswanathan</surname><given-names>K.</given-names></name><name><surname>Ganguly</surname><given-names>T.</given-names></name><name><surname>Elankumaran</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>S.</given-names></name><name><surname>Pelzer</surname><given-names>K.</given-names></name><name><surname>Lansing</surname><given-names>J.C.</given-names></name><name><surname>Sriranganathan</surname><given-names>N.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Galcheva-Gargova</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Contaminated heparin associated with adverse clinical events and activation of the contact system</article-title><source>N. Engl. J. Med.</source><year>2008</year><volume>358</volume><fpage>2457</fpage><lpage>2467</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0803200</pub-id><pub-id pub-id-type="pmid">18434646</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-10-00059"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szajek</surname><given-names>A.Y.</given-names></name><name><surname>Chess</surname><given-names>E.</given-names></name><name><surname>Johansen</surname><given-names>K.</given-names></name><name><surname>Gratzl</surname><given-names>G.</given-names></name><name><surname>Gray</surname><given-names>E.</given-names></name><name><surname>Keire</surname><given-names>D.</given-names></name><name><surname>Linhardt</surname><given-names>R.J.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Morris</surname><given-names>T.</given-names></name><name><surname>Mulloy</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The us regulatory and pharmacopeia response to the global heparin contamination crisis</article-title><source>Nat. Biotechnol.</source><year>2016</year><volume>34</volume><fpage>625</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1038/nbt.3606</pub-id><pub-id pub-id-type="pmid">27281424</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-10-00059"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keire</surname><given-names>D.A.</given-names></name><name><surname>Mulloy</surname><given-names>B.</given-names></name><name><surname>Chase</surname><given-names>C.</given-names></name><name><surname>Al-Hakim</surname><given-names>A.</given-names></name><name><surname>Cairatti</surname><given-names>D.</given-names></name><name><surname>Gray</surname><given-names>E.</given-names></name><name><surname>Hogwood</surname><given-names>J.</given-names></name><name><surname>Morris</surname><given-names>T.</given-names></name><name><surname>Mourao</surname><given-names>P.</given-names></name><name><surname>Soares</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Diversifying the global heparin supply chain reintroduction of bovine heparin in the united states?</article-title><source>Pharm. Technol.</source><year>2015</year><volume>39</volume><fpage>2</fpage><lpage>8</lpage></element-citation></ref><ref id="B4-pharmaceuticals-10-00059"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>U.</given-names></name><name><surname>Backstrom</surname><given-names>G.</given-names></name><name><surname>Thunberg</surname><given-names>L.</given-names></name></person-group><article-title>The antithrombin-binding sequence in heparin. Identification of an essential 6-<italic>O</italic>-sulfate group</article-title><source>J. Biol. Chem.</source><year>1983</year><volume>258</volume><fpage>9826</fpage><lpage>9830</lpage><pub-id pub-id-type="pmid">6885772</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-10-00059"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gresele</surname><given-names>P.</given-names></name><name><surname>Busti</surname><given-names>C.</given-names></name><name><surname>Paganelli</surname><given-names>G.</given-names></name></person-group><article-title>Heparin in the prophylaxis and treatment of venous thromboembolism and other thrombotic diseases</article-title><source>Handb. Exp. Pharmacol.</source><year>2012</year><volume>207</volume><fpage>179</fpage><lpage>209</lpage></element-citation></ref><ref id="B6-pharmaceuticals-10-00059"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>M.</given-names></name><name><surname>Crowther</surname><given-names>M.A.</given-names></name></person-group><article-title>Neutralization of heparin activity</article-title><source>Handb. Exp. Pharmacol.</source><year>2012</year><volume>207</volume><fpage>265</fpage><lpage>277</lpage></element-citation></ref><ref id="B7-pharmaceuticals-10-00059"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>L.C.</given-names></name><name><surname>Lee</surname><given-names>H.F.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>V.C.</given-names></name></person-group><article-title>Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (i): Preparation and characterization</article-title><source>AAPS PharmSci.</source><year>2001</year><volume>3</volume><fpage>E17</fpage><pub-id pub-id-type="doi">10.1208/ps030317</pub-id><pub-id pub-id-type="pmid">11741268</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-10-00059"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nybo</surname><given-names>M.</given-names></name><name><surname>Madsen</surname><given-names>J.S.</given-names></name></person-group><article-title>Serious anaphylactic reactions due to protamine sulfate: A systematic literature review</article-title><source>Basic Clin. Pharmacol. Toxicol.</source><year>2008</year><volume>103</volume><fpage>192</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1111/j.1742-7843.2008.00274.x</pub-id><pub-id pub-id-type="pmid">18816305</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-10-00059"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mecca</surname><given-names>T.</given-names></name><name><surname>Consoli</surname><given-names>G.M.</given-names></name><name><surname>Geraci</surname><given-names>C.</given-names></name><name><surname>La Spina</surname><given-names>R.</given-names></name><name><surname>Cunsolo</surname><given-names>F.</given-names></name></person-group><article-title>Polycationic calix[8]arenes able to recognize and neutralize heparin</article-title><source>Org. Biomol. Chem.</source><year>2006</year><volume>4</volume><fpage>3763</fpage><lpage>3768</lpage><pub-id pub-id-type="doi">10.1039/b608887b</pub-id><pub-id pub-id-type="pmid">17024282</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-10-00059"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalaska</surname><given-names>B.</given-names></name><name><surname>Kaminski</surname><given-names>K.</given-names></name><name><surname>Sokolowska</surname><given-names>E.</given-names></name><name><surname>Czaplicki</surname><given-names>D.</given-names></name><name><surname>Kujdowicz</surname><given-names>M.</given-names></name><name><surname>Stalinska</surname><given-names>K.</given-names></name><name><surname>Bereta</surname><given-names>J.</given-names></name><name><surname>Szczubialka</surname><given-names>K.</given-names></name><name><surname>Pawlak</surname><given-names>D.</given-names></name><name><surname>Nowakowska</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0119486</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0119486</pub-id><pub-id pub-id-type="pmid">25781030</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-10-00059"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shenoi</surname><given-names>R.A.</given-names></name><name><surname>Kalathottukaren</surname><given-names>M.T.</given-names></name><name><surname>Travers</surname><given-names>R.J.</given-names></name><name><surname>Lai</surname><given-names>B.F.</given-names></name><name><surname>Creagh</surname><given-names>A.L.</given-names></name><name><surname>Lange</surname><given-names>D.</given-names></name><name><surname>Yu</surname><given-names>K.</given-names></name><name><surname>Weinhart</surname><given-names>M.</given-names></name><name><surname>Chew</surname><given-names>B.H.</given-names></name><name><surname>Du</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants</article-title><source>Sci. Transl. Med.</source><year>2014</year><volume>6</volume><fpage>260ra150</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3009427</pub-id><pub-id pub-id-type="pmid">25355700</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-10-00059"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valimaki</surname><given-names>S.</given-names></name><name><surname>Khakalo</surname><given-names>A.</given-names></name><name><surname>Ora</surname><given-names>A.</given-names></name><name><surname>Johansson</surname><given-names>L.S.</given-names></name><name><surname>Rojas</surname><given-names>O.J.</given-names></name><name><surname>Kostiainen</surname><given-names>M.A.</given-names></name></person-group><article-title>Effect of peg-pdmaema block copolymer architecture on polyelectrolyte complex formation with heparin</article-title><source>Biomacromolecules</source><year>2016</year><volume>17</volume><fpage>2891</fpage><lpage>2900</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.6b00699</pub-id><pub-id pub-id-type="pmid">27477891</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-10-00059"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulloy</surname><given-names>B.</given-names></name><name><surname>Gray</surname><given-names>E.</given-names></name><name><surname>Barrowcliffe</surname><given-names>T.W.</given-names></name></person-group><article-title>Characterization of unfractionated heparin: Comparison of materials from the last 50 years</article-title><source>Thromb. Haemost.</source><year>2000</year><volume>84</volume><fpage>1052</fpage><lpage>1056</lpage><pub-id pub-id-type="pmid">11154113</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-10-00059"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St Ange</surname><given-names>K.</given-names></name><name><surname>Onishi</surname><given-names>A.</given-names></name><name><surname>Fu</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Mori</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Dordick</surname><given-names>J.S.</given-names></name><name><surname>Fareed</surname><given-names>J.</given-names></name><name><surname>Hoppensteadt</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Analysis of heparins derived from bovine tissues and comparison to porcine intestinal heparins</article-title><source>Clin. Appl. Thromb. Hemost.</source><year>2016</year><volume>22</volume><fpage>520</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1177/1076029616643822</pub-id><pub-id pub-id-type="pmid">27084870</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-10-00059"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertini</surname><given-names>S.</given-names></name><name><surname>Fareed</surname><given-names>J.</given-names></name><name><surname>Madaschi</surname><given-names>L.</given-names></name><name><surname>Risi</surname><given-names>G.</given-names></name><name><surname>Torri</surname><given-names>G.</given-names></name><name><surname>Naggi</surname><given-names>A.</given-names></name></person-group><article-title>Characterization of pf4-heparin complexes by photon correlation spectroscopy and zeta potential</article-title><source>Clin. Appl. Thromb. Hemost.</source><year>2017</year><pub-id pub-id-type="doi">10.1177/1076029616685430</pub-id><pub-id pub-id-type="pmid">28118750</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-10-00059"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tovar</surname><given-names>A.M.</given-names></name><name><surname>Capille</surname><given-names>N.V.</given-names></name><name><surname>Santos</surname><given-names>G.R.</given-names></name><name><surname>Vairo</surname><given-names>B.C.</given-names></name><name><surname>Oliveira</surname><given-names>S.N.</given-names></name><name><surname>Fonseca</surname><given-names>R.J.</given-names></name><name><surname>Mourao</surname><given-names>P.A.</given-names></name></person-group><article-title>Heparin from bovine intestinal mucosa: Glycans with multiple sulfation patterns and anticoagulant effects</article-title><source>Thromb. Haemost.</source><year>2012</year><volume>107</volume><fpage>903</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1160/TH-11-07-0518</pub-id><pub-id pub-id-type="pmid">22437650</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-10-00059"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommers</surname><given-names>C.D.</given-names></name><name><surname>Ye</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Linhardt</surname><given-names>R.J.</given-names></name><name><surname>Keire</surname><given-names>D.A.</given-names></name></person-group><article-title>Heparin and homogeneous model heparin oligosaccharides form distinct complexes with protamine: Light scattering and zeta potential analysis</article-title><source>J. Pharm. Biomed. Anal.</source><year>2017</year><volume>140</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2017.03.010</pub-id><pub-id pub-id-type="pmid">28346881</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-10-00059"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramamurthy</surname><given-names>N.</given-names></name><name><surname>Baliga</surname><given-names>N.</given-names></name><name><surname>Wakefield</surname><given-names>T.W.</given-names></name><name><surname>Andrews</surname><given-names>P.C.</given-names></name><name><surname>Yang</surname><given-names>V.C.</given-names></name><name><surname>Meyerhoff</surname><given-names>M.E.</given-names></name></person-group><article-title>Determination of low-molecular-weight heparins and their binding to protamine and a protamine analog using polyion-sensitive membrane electrodes</article-title><source>Anal. Biochem.</source><year>1999</year><volume>266</volume><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1006/abio.1998.2947</pub-id><pub-id pub-id-type="pmid">9887220</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-10-00059"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>M.</given-names></name><name><surname>Hogwood</surname><given-names>J.</given-names></name><name><surname>Gray</surname><given-names>E.</given-names></name><name><surname>Mulloy</surname><given-names>B.</given-names></name><name><surname>Hackett</surname><given-names>A.M.</given-names></name><name><surname>Johansen</surname><given-names>K.B.</given-names></name></person-group><article-title>Protamine neutralisation of low molecular weight heparins and their oligosaccharide components</article-title><source>Anal. Bioanal. Chem.</source><year>2011</year><volume>399</volume><fpage>763</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1007/s00216-010-4220-8</pub-id><pub-id pub-id-type="pmid">20922518</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-10-00059"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tovar</surname><given-names>A.M.</given-names></name><name><surname>Santos</surname><given-names>G.R.</given-names></name><name><surname>Capille</surname><given-names>N.V.</given-names></name><name><surname>Piquet</surname><given-names>A.A.</given-names></name><name><surname>Glauser</surname><given-names>B.F.</given-names></name><name><surname>Pereira</surname><given-names>M.S.</given-names></name><name><surname>Vilanova</surname><given-names>E.</given-names></name><name><surname>Mourao</surname><given-names>P.A.</given-names></name></person-group><article-title>Structural and haemostatic features of pharmaceutical heparins from different animal sources: Challenges to define thresholds separating distinct drugs</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>35619</fpage><pub-id pub-id-type="doi">10.1038/srep35619</pub-id><pub-id pub-id-type="pmid">27752111</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-10-00059"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhakal</surname><given-names>P.</given-names></name><name><surname>Rayamajhi</surname><given-names>S.</given-names></name><name><surname>Verma</surname><given-names>V.</given-names></name><name><surname>Gundabolu</surname><given-names>K.</given-names></name><name><surname>Bhatt</surname><given-names>V.R.</given-names></name></person-group><article-title>Reversal of anticoagulation and management of bleeding in patients on anticoagulants</article-title><source>Clin. Appl. Thromb. Hemost.</source><year>2016</year><pub-id pub-id-type="doi">10.1177/1076029616675970</pub-id><pub-id pub-id-type="pmid">27789605</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-10-00059"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>E.</given-names></name><name><surname>Hogwood</surname><given-names>J.</given-names></name><name><surname>Mulloy</surname><given-names>B.</given-names></name></person-group><article-title>The anticoagulant and antithrombotic mechanisms of heparin</article-title><source>Handb. Exp. Pharmacol.</source><year>2012</year><volume>207</volume><fpage>43</fpage><lpage>61</lpage></element-citation></ref><ref id="B23-pharmaceuticals-10-00059"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panagos</surname><given-names>C.G.</given-names></name><name><surname>Thomson</surname><given-names>D.S.</given-names></name><name><surname>Moss</surname><given-names>C.</given-names></name><name><surname>Hughes</surname><given-names>A.D.</given-names></name><name><surname>Kelly</surname><given-names>M.S.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Chai</surname><given-names>W.</given-names></name><name><surname>Venkatasamy</surname><given-names>R.</given-names></name><name><surname>Spina</surname><given-names>D.</given-names></name><name><surname>Page</surname><given-names>C.P.</given-names></name><etal/></person-group><article-title>Fucosylated chondroitin sulfates from the body wall of the sea cucumber holothuria forskali: Conformation, selectin binding, and biological activity</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>28284</fpage><lpage>28298</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.572297</pub-id><pub-id pub-id-type="pmid">25147180</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-10-00059"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulloy</surname><given-names>B.</given-names></name><name><surname>Hogwood</surname><given-names>J.</given-names></name></person-group><article-title>Chromatographic molecular weight measurements for heparin, its fragments and fractions, and other glycosaminoglycans</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>1229</volume><fpage>105</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">25325948</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-10-00059"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boothello</surname><given-names>R.S.</given-names></name><name><surname>Al-Horani</surname><given-names>R.A.</given-names></name><name><surname>Desai</surname><given-names>U.R.</given-names></name></person-group><article-title>Glycosaminoglycan-protein interaction studies using fluorescence spectroscopy</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>1229</volume><fpage>335</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">25325964</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceuticals-10-00059-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Scatter Plots of specific activities, and interquartile range for porcine intestinal mucosa (PM), bovine intestinal mucosa (BM) and bovine lung (BL) heparin samples. Activities have been calculated relative to the 6th International standard for Unfractionated Heparin (porcine heparin) using parallel line bioassay model for all assays. All samples compared validly to the standard, passing the ANOVA criteria for parallelism and linearity. AT:aXa&#x02014;antithrombin dependent anti-Xa; AT:aIIa&#x02014;antithrombin dependent anti-IIa, APTT&#x02014;plasma APTT assay; HCII:aIIa&#x02014;heparin cofactor II dependent anti-IIa.</p></caption><graphic xlink:href="pharmaceuticals-10-00059-g001"/></fig><fig id="pharmaceuticals-10-00059-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Amount of heparin in International Units (anti-IIa) that is required to precipitate 1 mg of protamine sulfate, estimated according to the European Pharmacopeia assay for protamine sulfate. (error bars = standard deviation, <italic>n</italic> = 9).</p></caption><graphic xlink:href="pharmaceuticals-10-00059-g002"/></fig><fig id="pharmaceuticals-10-00059-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Amount of heparin in mg (calculated from anti-IIa specific activity) that is required to precipitate out 1 mg of protamine sulfate, estimated according to the European Pharmacopeia assay for protamine sulfate. (error bars = standard deviation, <italic>n</italic> = 9).</p></caption><graphic xlink:href="pharmaceuticals-10-00059-g003"/></fig><fig id="pharmaceuticals-10-00059-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Remaining activity from precipitation and neutralization assays for each heparin sample. Potency shown above has been calculated from mixture of 100 IU/mL heparin with 0.5 mg/mL protamine sulfate, precipitation assay value has been calculated from the protamine sulfate assay, AT:aIIa, AT:aXa, APTT and HCII:aIIa are residual potency estimations. AT:aIIa&#x02014;antithrombin dependent anti-IIa, AT:aXa&#x02014;antithrombin dependent anti-Xa, APTT&#x02014;plasma APTT clotting assay, HCII:aIIa&#x02014;Heparin Cofactor II dependent anti-IIa. Error bars are SD for precipitation assay, and upper 95% confidence limit for other assays.</p></caption><graphic xlink:href="pharmaceuticals-10-00059-g004"/></fig><fig id="pharmaceuticals-10-00059-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Activated clotting from thromboelastography and clotting times from APTT assay of heparin samples at 1 IU/mL without (P1, B1, B2 etc.) or with 0.05 mg/mL protamine sulfate added (P1+, B1+, B2+ etc.) in whole blood. Data shown are the blank corrected clotting times averaged from six individual blood donors, a 0 s time would indicate that all heparin present has been neutralized. (<italic>n</italic> = 6, error bars = SDs).</p></caption><graphic xlink:href="pharmaceuticals-10-00059-g005"/></fig><fig id="pharmaceuticals-10-00059-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Antithrombin fluorescent titration assay with % high affinity antithrombin binding material within each heparin preparations. High affinity material calculated using the number average molecular weight Mn for each heparin and the concentration of heparin required to titrate antithrombin to generate a maximum change in fluorescent signal. (<italic>n</italic> = 4, error bars = SDs).</p></caption><graphic xlink:href="pharmaceuticals-10-00059-g006"/></fig><table-wrap id="pharmaceuticals-10-00059-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-10-00059-t001_Table 1</object-id><label>Table 1</label><caption><p>Protamine Sulfate precipitation results for heparin samples by IU/mg and mg/mg. Results show the mean and range for each heparin type for IU (anti-IIa) to mg protamine and recalculated for mg (anti-IIa) to mg protamine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PM (<italic>n</italic> = 16)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BM (<italic>n</italic> = 16)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BL (<italic>n</italic> = 4)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>-Values</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>IU/mg PS Mean (range)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">126 (103&#x02013;142)</td><td align="center" valign="middle" rowspan="1" colspan="1">79.4 (48.4&#x02013;96.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">84.3 (79.0&#x02013;95.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">PM&#x02013;BM &#x0003c; 0.001; PM&#x02013;BL &#x0003c; 0.001; BM&#x02013;BL = 0.233</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>mg/mg PS Mean (range)</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76 (0.67&#x02013;0.84)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76 (0.70&#x02013;0.82)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74 (0.68&#x02013;0.84)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM&#x02013;BM = 0.403; PM&#x02013;BL = 0.289; BM&#x02013;BL = 0.188</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceuticals-10-00059-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-10-00059-t002_Table 2</object-id><label>Table 2</label><caption><p>Selected heparins (four each of PM, BM and BL heparins) IU (AT:aIIa) required to precipitate 1 mg protamine sulfate. Samples here are not PM 1&#x02013;4 or BM 1&#x02013;4 as indicated in <xref ref-type="fig" rid="pharmaceuticals-10-00059-f002">Figure 2</xref> and <xref ref-type="fig" rid="pharmaceuticals-10-00059-f003">Figure 3</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Sample Code and IU Heparin/mg Protamine</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM</td><td align="center" valign="middle" rowspan="1" colspan="1">P1</td><td align="center" valign="middle" rowspan="1" colspan="1">P2</td><td align="center" valign="middle" rowspan="1" colspan="1">P3</td><td align="center" valign="middle" rowspan="1" colspan="1">P4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">142</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">135</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">121</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">BM</td><td align="center" valign="middle" rowspan="1" colspan="1">B1</td><td align="center" valign="middle" rowspan="1" colspan="1">B2</td><td align="center" valign="middle" rowspan="1" colspan="1">B3</td><td align="center" valign="middle" rowspan="1" colspan="1">B4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">BL</td><td align="center" valign="middle" rowspan="1" colspan="1">L1</td><td align="center" valign="middle" rowspan="1" colspan="1">L2</td><td align="center" valign="middle" rowspan="1" colspan="1">L3</td><td align="center" valign="middle" rowspan="1" colspan="1">L4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceuticals-10-00059-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-10-00059-t003_Table 3</object-id><label>Table 3</label><caption><p>Average amount of heparin which 1 mg of protamine sulfate can precipitate or neutralize. (&#x000b1;SDs).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">By EP Precipitation Assay</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">By Neutralization of Biological Activity</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Ave (<italic>n</italic> = 4)</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IU anti-IIa/mg protamine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mg heparin/mg protamine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IU anti-IIa/mg protamine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mg heparin/mg protamine</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>PM</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">131 (&#x000b1;9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.73 (&#x000b1;0.02)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">161 (&#x000b1;6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.90 (&#x000b1;0.06)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>BM</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75 (&#x000b1;14)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75 (&#x000b1;0.04)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123 (&#x000b1;9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.26 (&#x000b1;0.19)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>BL</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84 (&#x000b1;8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74 (&#x000b1;0.07)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">131 (&#x000b1;15)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.16 (&#x000b1;0.15)</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceuticals-10-00059-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-10-00059-t004_Table 4</object-id><label>Table 4</label><caption><p>Molecular Weight of heparin samples, determined against the USP Unfractionated Heparin Molecular Weight Standard, results are average from two determinations. Mp = peak molecular weight, Mn = number average molecular weight, Mw weight average molecular weight, PD = polydispersity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mp</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mn</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mw</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% &#x0003c; 8 kDa</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Porcine Mucosa</td><td align="center" valign="middle" rowspan="1" colspan="1">P1</td><td align="center" valign="middle" rowspan="1" colspan="1">15,800</td><td align="center" valign="middle" rowspan="1" colspan="1">13,820</td><td align="center" valign="middle" rowspan="1" colspan="1">17,870</td><td align="center" valign="middle" rowspan="1" colspan="1">1.29</td><td align="center" valign="middle" rowspan="1" colspan="1">8.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">P2</td><td align="center" valign="middle" rowspan="1" colspan="1">16,110</td><td align="center" valign="middle" rowspan="1" colspan="1">13,900</td><td align="center" valign="middle" rowspan="1" colspan="1">17,290</td><td align="center" valign="middle" rowspan="1" colspan="1">1.24</td><td align="center" valign="middle" rowspan="1" colspan="1">7.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">P3</td><td align="center" valign="middle" rowspan="1" colspan="1">16,320</td><td align="center" valign="middle" rowspan="1" colspan="1">14,140</td><td align="center" valign="middle" rowspan="1" colspan="1">17,390</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,080</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,080</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,720</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.4</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bovine Mucosa</td><td align="center" valign="middle" rowspan="1" colspan="1">B1</td><td align="center" valign="middle" rowspan="1" colspan="1">13,230</td><td align="center" valign="middle" rowspan="1" colspan="1">11,660</td><td align="center" valign="middle" rowspan="1" colspan="1">14,750</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">15.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">B2</td><td align="center" valign="middle" rowspan="1" colspan="1">16,140</td><td align="center" valign="middle" rowspan="1" colspan="1">14,980</td><td align="center" valign="middle" rowspan="1" colspan="1">17,950</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">4.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">B3</td><td align="center" valign="middle" rowspan="1" colspan="1">14,130</td><td align="center" valign="middle" rowspan="1" colspan="1">12,920</td><td align="center" valign="middle" rowspan="1" colspan="1">15,920</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23</td><td align="center" valign="middle" rowspan="1" colspan="1">9.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,940</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,670</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,430</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.8</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bovine Lung</td><td align="center" valign="middle" rowspan="1" colspan="1">L1</td><td align="center" valign="middle" rowspan="1" colspan="1">9700</td><td align="center" valign="middle" rowspan="1" colspan="1">11,280</td><td align="center" valign="middle" rowspan="1" colspan="1">14,450</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28</td><td align="center" valign="middle" rowspan="1" colspan="1">18.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L2</td><td align="center" valign="middle" rowspan="1" colspan="1">8770</td><td align="center" valign="middle" rowspan="1" colspan="1">10,570</td><td align="center" valign="middle" rowspan="1" colspan="1">13,380</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">22.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L3</td><td align="center" valign="middle" rowspan="1" colspan="1">8810</td><td align="center" valign="middle" rowspan="1" colspan="1">9740</td><td align="center" valign="middle" rowspan="1" colspan="1">12,160</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9720</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,310</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,360</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.5</td></tr></tbody></table></table-wrap></floats-group></article>